Windtree Therapeutics Files 8-K on Security Holder Vote Matters
Ticker: WINTW · Form: 8-K · Filed: Sep 2, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: WINT
TL;DR
Windtree Therapeutics is having a shareholder vote soon, details to follow.
AI Summary
On August 28, 2025, Windtree Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not specify the exact matters to be voted on or the date of the security holder meeting.
Why It Matters
This filing indicates that Windtree Therapeutics is seeking approval from its shareholders on certain corporate actions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can introduce uncertainty regarding corporate governance and strategic decisions.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- August 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (address) — Principal executive offices
FAQ
What specific matters will be submitted for a vote of security holders?
The filing does not specify the exact matters to be submitted for a vote of security holders; it only states that such a submission is occurring.
When is the security holder meeting or vote scheduled to take place?
The filing does not provide a date for the security holder meeting or the vote.
What is the purpose of submitting these matters to a vote?
The filing does not explicitly state the purpose, but typically such votes are for corporate actions requiring shareholder approval, such as mergers, acquisitions, or amendments to corporate governance.
Has Windtree Therapeutics previously filed similar 8-K reports regarding security holder votes?
This filing is a current report (8-K) dated August 28, 2025. The filing itself does not provide historical context on previous similar filings.
Where can shareholders find more information about the matters to be voted on?
Typically, detailed information would be provided in a proxy statement (DEF 14A) filed with the SEC, which is not included in this 8-K filing.
Filing Stats: 1,230 words · 5 min read · ~4 pages · Grade level 15.7 · Accepted 2025-09-02 17:16:05
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The OTCID Market In
Filing Documents
- wint20250902_8k.htm (8-K) — 57KB
- 0001437749-25-028170.txt ( ) — 181KB
- wint-20250828.xsd (EX-101.SCH) — 3KB
- wint-20250828_def.xml (EX-101.DEF) — 11KB
- wint-20250828_lab.xml (EX-101.LAB) — 14KB
- wint-20250828_pre.xml (EX-101.PRE) — 11KB
- wint20250902_8k_htm.xml (XML) — 3KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On August 28, 2025, Windtree Therapeutics, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") virtually. As of July 23, 2025, the record date for the Special Meeting, there were 28,658,826 outstanding shares of the Company's common stock. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Special Meeting, which are described in the Company's Definitive Proxy Statement on Schedule 14A for the Special Meeting, filed with the U.S. Securities and Exchange Commission on August 8, 2025. (a) Proposal 1 - Approval of the issuance of the Series D Convertible Shares, in accordance with Nasdaq Listing Rules 5635 (b) and (d), upon the conversion of our Series D Preferred Stock. The votes with respect to the approval of the issuance of the Series D Convertible Shares, in accordance with Nasdaq Listing Rules 5635 (b) and (d), upon the conversion of our Series D Preferred Stock, were as follows: Votes For Votes Against Abstentions Broker Non-Votes 1,205,702 169,926 69,021 9,617,998 (b) Proposal 2 - Approval of the issuance of the Note Conversion Shares, in accordance with Nasdaq Listing Rules 5635 (b) and (d), upon the conversion of the Promissory Notes. The votes with respect to the approval of the issuance of the Note Conversion Shares, in accordance with Nasdaq Listing Rules 5635 (b) and (d), upon the conversion of the Promissory Notes, were as follows: Votes For Votes Against Abstentions Broker Non-Votes 1,071,631 285,069 87,949 9,617,998 (c) Proposal 3 - Approval of the issuance of the PIPE Warrant Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the exercise of our PIPE Warrants. The votes with respect to the approval of the issuance of the PIPE Warrant Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the exerc
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: September 2, 2025